This article is more than 5 years old. Information may no longer be current.
Top stories in gastroenterology: FDA approves non-surgical weight loss device for obesity, narrow band imaging best at detecting adenomas
Click Here to Manage Email Alerts
Among the top stories in gastroenterology last week were the FDA approving a non-surgical weight loss device for adults with obesity and a meta-analysis that found narrow band imaging was the best at detecting adenomas when bowel preparation was of the highest quality.
Other highlights included research that suggested personalized surveillance can help reduce the colonoscopy burden among patients with lower risk serrated polyposis syndrome, a study that found treatment with radiofrequency ablation improved the outlook for patients with Barrett’s esophagus and data that indicated Humira and Remicade were both equally effective for treating postoperative recurrence of Crohn’s disease.
FDA approves non-surgical weight loss device for obesity
The FDA has approved a non-surgical weight loss device for adults with obesity and have a body mass index of 30 kg/m2 to 40 kg/m2, according to a press release. Read more.
When bowel prep is best, narrow band imaging reigns in adenoma detection
Narrow band imaging appeared to be the best at detecting adenomas, according to a meta-analysis published in Gastroenterology, but only at the highest quality bowel preparation. Read more.
Low-risk serrated polyposis syndrome comes with lower colonoscopy burden
Personalized surveillance can help reduce the colonoscopy burden among patients with lower risk serrated polyposis syndrome, according to research published in Gut. Read more.
Ablation helps improve outlook for patients with Barrett’s
Patients treated with radiofrequency ablation for Barrett’s esophagus with low-grade dysplasia felt less threatened by their condition than patients who underwent normal surveillance, according to research published in Gastrointestinal Endoscopy. Read more.
Efficacy of anti-tumor necrosis factors similar in postoperative Crohn’s recurrence
Humira and Remicade are equally effective for treating postoperative recurrence of Crohn’s disease, according to data from clinical practice. Read more.